Correction to “Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsImmunotherapy and Immune Responses · Hepatitis B Virus Studies
Mai J, Li Z, Xia X, Zhang J, Li J, Liu H, Shen J, Ramirez M, Li F, Li Z, Yokoi K, Liu X, Mittendorf EA, Ferrari M, Shen H. Adv Sci (Weinh). 2021, 8:2100166.
https://doi.org/10.1002/advs.202100166
In paragraph 1 of the “Discussion and Conclusion” section, a new reference “B. Temizoz, E. Kuroda, K. Ohata, N. Jounai, K. Ozasa, K. Kobiyama, T. Aoshi, and K.J. Ishii, Eur J Immunol. 2015, 45, 1159” is added after the text “… potentially as a result of crosstalk between the TLR and STING‐mediated pathways and m‐particle‐activated TRIF/MAVS signaling”.
In paragraph 3 of the “Discussion and Conclusion” section, a new reference “C. Aroh, Z. Wang, N. Dobbs, M. Luo, Z. Chen, J. Gao, N. Yan, J Immunol. 2017, 199, 3840” is added after the text “In line with the study, it was previous found that a nanoparticle‐based vaccine carrying a STING‐activating polymer provided better therapeutic outcome than a polyIC‐based vaccine.”
We apologize for missing these two references in the original article.